|
| Study | Model | RNAi-silencing | Effects | Ref |
|
| Denkert et al. 2003 | OVCAR-3 cells (human ovarian carcinoma) | siCOX-2 (short term expression) | - COX-2 protein silencing | |
| - Reduction of PGE2 levels | [32] |
| - No effects on cell proliferation | |
|
| Strillacci et al. 2006 | HUVECs (human umbilical vein endothelial cells) | siCOX-2 (short term expression) | - COX-2 protein silencing | |
| - Reduction of 6-keto- levels | |
| - Reduction of capillary-like tubular | [39] |
| structures on 3D collagen gel | |
| - No effects on interferon system | |
|
| Strillacci et al. 2006 | HT-29 cells (human colon carcinoma) | shCOX-2 (stable expression) | - COX-2 protein and mRNA silencing | |
| - Reduction of PGE2 levels | |
| - No effects on interferon system | [39] |
| - No effects on cell proliferation | |
| - Impairment of malignant behavior | |
|
| Charames and Bapat 2006 | HT-29 cells (human colon carcinoma) | siCOX-2 (short term expression) | - COX-2 protein and mRNA silencing | [33] |
| - No effects on cell apoptosis | |
|
| Kobayashi et al. 2007 | CG cells (bovine Cumulus Granulosa) | siCOX-2 (short-term expression) | - COX-2 mRNA silencing | [34] |
| - Reduction of levels | |
|
| Wang et al. 2008 | Hep-2 cells (human laryngeal carcinoma) | shCOX-2 (stable expression) | - COX-2 protein and mRNA silencing | |
| - Inhibition of proliferation | |
| - Impairment of malignant behavior | [40] |
| - Inhibition of in vivo growth | |
| - Enhanced chemosensitivity in vitro and in vivo | |
|
| Sansone et al. 2008 | HT-29 cells (human colon carcinoma) | shCOX-2 (stable expression) | - COX-2 protein and mRNA silencing | |
| - Inhibition of Erk phosphorilation | |
| - Inhibition of CA-IX expression | |
| - Inhibition of cell invasion | [41] |
| - Inhibition of MMP-2 activation | |
| - No effects on cell death | |
| - Inhibition of hypoxic survival | |
|
